Influences on serum concentrations of morphine, M6G and M3G during routine clinical drug monitoring: A prospective survey in 300 adult cancer patients
- 13 June 2003
- journal article
- clinical trial
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 47 (6) , 725-731
Abstract
Background: In order to make treatment decisions physicians should have knowledge about the relations between patient characteristics and drug disposition. Dose, route of administration, gender, age and renal function are reported to influence the serum concentrations of morphine, morphine‐6‐glucurnide (M6G) and morphine‐3‐glucuronide (M3G) during chronic treatment of cancer pain. These factors, however, are not evaluated in studies with a sample size sufficient to explore predictive factors.Methods: Three hundred consecutive morphine users admitted because of a malignant disease were recruited. The relations of serum concentrations of morphine, M6G and M3G to patient characteristics (gender, age, weight, renal function, liver function, dose, route of administration) were explored, and regression analysis performed to investigate whether these characteristics predicted serum concentrations obtained during routine clinical drug monitoring.Results: Morphine dose was associated with serum concentrations of morphine (r = 0.69), M6G (r = 0.76) and M3G (r = 0.76). Oral morphine resulted in higher dose‐adjusted M6G and M3G serum concentrations compared with s.c. morphine. Creatinine serum concentrations correlated with serum concentrations of M6G and M3G. Dose and route of administration predicted morphine serum concentrations, while dose and renal function predicted M6G and M3G serum concentrations. Age was an additional factor predicting M3G concentrations. Dose was the only factor that explained a clinically significant part of the observed variability.Conclusion: Patient characteristics predict only minor parts of the variability of morphine, M3G and M6G serum concentrations observed during routine clinical drug‐monitoring in cancer patients.Keywords
This publication has 19 references indexed in Scilit:
- Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphineEuropean Journal of Clinical Pharmacology, 2000
- Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long‐term administration?: Six case historiesActa Anaesthesiologica Scandinavica, 1998
- Systematic review of factors affecting the ratios of morphine and its major metabolitesPain, 1998
- Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatientsJournal of Pain and Symptom Management, 1997
- Pharmacokinetic Parameters Relevant to Recovery from OpioidsAnesthesiology, 1994
- Myoclonic spasms during treatment with high doses of intravenous morphine in renal failureActa Anaesthesiologica Scandinavica, 1993
- MORPHINE-6-GLUCURONIDE DISPOSITION IN RENAL IMPAIRMENTBritish Journal of Anaesthesia, 1993
- The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal functionClinical Pharmacology & Therapeutics, 1992
- Oral morphine in cancer pain: influences on morphine and metabolite concentrationClinical Pharmacology & Therapeutics, 1990
- Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administrationEuropean Journal of Clinical Pharmacology, 1990